# Analysis: GILD_2024_Q4.txt

*Model: gpt-4o*

---

**Quarter & Company Context**
- **Company Name:** Gilead Sciences, Inc.
- **Ticker:** GILD
- **Fiscal Quarter/Year:** Fourth Quarter and Full Year 2024
- **Key Macro or Industry Context:** Management highlighted the impact of Medicare Part D reform on future revenue growth, particularly affecting the HIV segment. The company is also navigating a post-pandemic environment with decreased COVID-19 hospitalizations affecting Veklury sales.

**Headline Financial Results**
- **Revenue:** Total product sales for 2024 were $28.6 billion, a 6% increase from 2023. Excluding Veklury, sales were $26.8 billion, up 8% year-over-year.
- **EPS:** Non-GAAP EPS was $4.62, reflecting a $3.14 per share impact from the SimiBay acquisition. Excluding this, EPS would have been $7.75, up 15% from 2023.
- **Margins:** Operating margin was 30%, impacted by the SimiBay acquisition. Excluding this, the margin would have been 43%.
- **Guidance:** For 2025, Gilead expects total product sales of $28.2 to $28.6 billion, with non-GAAP EPS between $7.70 and $8.10.

**Management Commentary**
- **Strategic Initiatives:** Gilead is focusing on expanding its HIV portfolio with the anticipated launch of Lenacapivir for HIV prevention. The company is also advancing its oncology and inflammation pipelines, including new trials for Trodelvi and cell therapies.
- **Risks/Challenges:** The Medicare Part D reform is expected to impact 2025 revenue by approximately $1.1 billion, primarily affecting the HIV segment. Competitive pressures in the cell therapy market are also noted.

**Q&A Highlights**
- **Main Themes:** Analysts focused on the launch dynamics of Lenacapivir, the impact of Medicare reforms, and the competitive landscape in oncology and cell therapy.
- **Management Tone:** Management expressed confidence in the strategic direction and growth potential, particularly in HIV and oncology, while acknowledging challenges from regulatory changes and competitive pressures.

**Market/Investor Sentiment Signals**
- **Forward-looking Commentary:** Management expects continued demand growth across therapeutic areas, with strategic launches anticipated to drive future growth. Cost control measures are expected to enhance margins.
- **Surprises vs. Expectations:** The strong demand for Livdelzy and the robust growth in the HIV segment were positive surprises, while the impact of Medicare reforms was a noted headwind.

**Takeaways**
- Gilead reported strong revenue growth driven by its HIV portfolio, with Biktarvy and Descovy leading the charge.
- The company is preparing for the launch of Lenacapivir, which is expected to be a significant growth driver in the HIV prevention market.
- Medicare Part D reform poses a challenge for 2025 revenue, particularly impacting the HIV segment.
- Gilead's oncology and inflammation pipelines are progressing, with key trials and potential approvals on the horizon.
- Management remains focused on disciplined expense management to support margin expansion.

**Other Notable Information**
- **Leadership Changes:** Dietmar Berger was introduced as the new Chief Medical Officer, bringing extensive experience in global drug development.
- **Regulatory Updates:** Lenacapivir has been filed for approval in the U.S. and Europe, with breakthrough therapy designation from the FDA.
- **Legal/Regulatory:** A litigation accrual was noted for a potential settlement with the U.S. Attorney's Office regarding promotional speaker programs for HIV medicines.